Global Monoclonal Antibodies Market 2022-2028

April 2022 | 72 pages | ID: G7528145DD3DEN
Gen Consulting Company

Abstracts

Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, modify or mimic the immune system's attack on cells that aren't wanted, such as cancer cells. Monoclonal antibodies have been approved to treat cancer, cardiovascular disease, inflammatory diseases, macular degeneration, transplant rejection, multiple sclerosis and viral infection. The global monoclonal antibodies market is likely to register a CAGR of over 10.2% with an incremental growth of USD 108 billion during the forecast period 2022-2028.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global monoclonal antibodies market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the monoclonal antibodies industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, manufacturing process, indication, application, end user, and region. The global market for monoclonal antibodies can be segmented by product: chimeric monoclonal antibodies, human monoclonal antibodies, humanized monoclonal antibodies, murine monoclonal antibodies. The human monoclonal antibodies segment was the largest contributor to the global monoclonal antibodies market in 2021. Monoclonal antibodies market is further segmented by manufacturing process: mammalian cell culture, microbial fermentation. Based on indication, the monoclonal antibodies market is segmented into: cancer, autoimmune diseases, infectious diseases, inflammatory diseases, others. On the basis of application, the monoclonal antibodies market also can be divided into: therapeutic, diagnostic, research. Monoclonal antibodies market by end user is categorized into: hospitals, research institutes, others. The monoclonal antibodies market by region can be segmented into: North America, Asia Pacific, Europe, Rest of the World (ROW).

By product:

• chimeric monoclonal antibodies
• human monoclonal antibodies
• humanized monoclonal antibodies
• murine monoclonal antibodies

By manufacturing process:

• mammalian cell culture
• microbial fermentation

By indication:

• cancer
• autoimmune diseases
• infectious diseases
• inflammatory diseases
• others

By application:

• therapeutic
• diagnostic
• research

By end user:

• hospitals
• research institutes
• others

By region:

• North America
• Asia Pacific
• Europe
• Rest of the World (ROW)

The report also provides analysis of the key companies of the industry and their detailed company profiles including AbbVie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Novartis International AG, among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global monoclonal antibodies market.
• To classify and forecast the global monoclonal antibodies market based on product, manufacturing process, indication, application, end user, region.
• To identify drivers and challenges for the global monoclonal antibodies market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global monoclonal antibodies market.
• To identify and analyze the profile of leading players operating in the global monoclonal antibodies market.

Why Choose This Report

• Gain a reliable outlook of the global monoclonal antibodies market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY PRODUCT

Chimeric monoclonal antibodies
Human monoclonal antibodies
Humanized monoclonal antibodies
Murine monoclonal antibodies

PART 6. MARKET BREAKDOWN BY MANUFACTURING PROCESS

Mammalian cell culture
Microbial fermentation

PART 7. MARKET BREAKDOWN BY INDICATION

Cancer
Autoimmune diseases
Infectious diseases
Inflammatory diseases
Others

PART 8. MARKET BREAKDOWN BY APPLICATION

Therapeutic
Diagnostic
Research

PART 9. MARKET BREAKDOWN BY END USER

Hospitals
Research institutes
Others

PART 10. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 11. KEY COMPANIES

AbbVie Inc.
Amgen Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline plc.
Johnson & Johnson
Merck & Co., Inc.
Novartis International AG
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER